Comment

Chief nurse Kate Holliday notes that for the industry, this shift highlights the ongoing need to engage with primary care nurses. Yet the expertise of nurses continues to be overlooked in some key healthcare decision-making committees, despite their critical contributions, she says.

Stakeholders, including pharmacy, have welcomed new guidelines from the Australian Health Practitioner Regulation Agency for practitioners who prescribe and dispense medicinal cannabis.

Australia's approach might be justified on public health grounds, but let's drop the hypocrisy. Australia effectively applies reverse tariffs on some pharmaceuticals and health products.

The current debate about the US applying tariffs to pharmaceutical imports and demands for PBS reforms is the most ludicrous in the recent history of the program.

Australian antiviral drug development company, Island Pharmaceuticals (ASX:ILA), has signed an agreement to acquire the galidesivir antiviral program from US-based BioCryst Pharmaceuticals.

The Department of Health, Disability and Ageing has revealed that health spending is under increasing pressure in its Incoming Government Brief to Health Minister Mark Butler.

AusBiotech has marked the first half of 2025 by confirming 27 new member organisations, including multinational biopharmaceutical companies.

Patients Australia has convened a new consortium comprised of a range of private healthcare providers to develop new standards for the telehealth sector.

MedAdvisor CEO and managing director, Rick Ratliff, said, "We are now sharpening our focus on the US business. While near-term market headwinds persist, we remain confident in the strength of our platform, the depth of our client relationships, and the strategic investments positioning us for long-term growth."

The South Australian Government has responded to a significant seasonal flu outbreak by announcing it will fund pharmacies to administer the vaccines to children aged six months to five years.

Setting aside the lack of utility of these documents, which provide virtually incomprehensible explanations for demanding price reductions, the information they contain belongs to the sponsor companies, who have every right to delay or prevent their publication.

Neurotech International (ASX: NTI) has announced the publication of its Phase 1/2 clinical trial results for Rett syndrome in the peer-reviewed scientific journal, Journal of Paediatrics and Child Health.